{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:29:32Z","timestamp":1789597772508,"version":"build-2803163510"},"reference-count":34,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2023,7,10]]},"DOI":"10.1253\/circrep.cr-23-0022","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T22:27:21Z","timestamp":1687472841000},"page":"298-305","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence and Treatment of Arrhythmias in Patients With Transthyretin and Light-Chain Cardiac Amyloidosis"],"prefix":"10.1253","volume":"5","author":[{"given":"Masakazu","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazufumi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiro","family":"Nishii","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"},{"name":"Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Ueoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Asada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuyuki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"},{"name":"Department of Cardiology, National Hospital Organization Okayama Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"},{"name":"Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. <i>N Engl J Med<\/i> 2003; 349: 583\u2013596, doi:10.1056\/NEJMra023144.","DOI":"10.1056\/NEJMra023144"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types. <i>Circulation<\/i> 2009; 120: 1203\u20131212, doi:10.1161\/CIRCULATIONAHA.108.843334.","DOI":"10.1161\/CIRCULATIONAHA.108.843334"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Saito Y, Nakamura K, Ito H. Molecular mechanisms of cardiac amyloidosis. <i>Int J Mol Sci<\/i> 2021; 23: 25, doi:10.3390\/ijms23010025.","DOI":"10.3390\/ijms23010025"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Inomata T, Tahara N, Nakamura K, Endo J, Ueda M, Ishii T, et al. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: Red-flag symptom clusters and diagnostic algorithm. <i>ESC Heart Fail<\/i> 2021; 8: 2647\u20132659, doi:10.1002\/ehf2.13473.","DOI":"10.1002\/ehf2.13473"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. <i>Circ Heart Fail<\/i> 2019; 12: e005407, doi:10.1161\/CIRCHEARTFAILURE.118.005407.","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Westin O, Butt JH, Gustafsson F, Schou M, Salomo M, Kober L, et al. Two decades of cardiac amyloidosis: A Danish nationwide study. <i>JACC CardioOncol<\/i> 2021; 3: 522\u2013533, doi:10.1016\/j.jaccao.2021.05.004.","DOI":"10.1016\/j.jaccao.2021.05.004"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Bajwa F, O\u2019Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. <i>Heart Fail Rev<\/i> 2022; 27: 1471\u20131484, doi:10.1007\/s10741-021-10162-1.","DOI":"10.1007\/s10741-021-10162-1"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Izumiya Y, Takashio S, Oda S, Yamashita Y, Tsujita K. Recent advances in diagnosis and treatment of cardiac amyloidosis. <i>J Cardiol<\/i> 2018; 71: 135\u2013143, doi:10.1016\/j.jjcc.2017.10.003.","DOI":"10.1016\/j.jjcc.2017.10.003"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, et al. A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2019; 84: 15\u201317, doi:10.1253\/circj.CJ-19-0811.","DOI":"10.1253\/circj.CJ-19-0811"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016, doi:10.1056\/NEJMoa1805689.","DOI":"10.1056\/NEJMoa1805689"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. <i>N Engl J Med<\/i> 2018; 379: 11\u201321, doi:10.1056\/NEJMoa1716153.","DOI":"10.1056\/NEJMoa1716153"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. <i>N Engl J Med<\/i> 2021; 385: 46\u201358, doi:10.1056\/NEJMoa2028631.","DOI":"10.1056\/NEJMoa2028631"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. <i>Circulation<\/i> 2016; 133: 2404\u20132412, doi:10.1161\/CIRCULATIONAHA.116.021612.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Nishi M, Takashio S, Morioka M, Fujiyama A, Nakashima N, Hirakawa K, et al. Extracardiac biopsy sensitivity in transthyretin amyloidosis cardiomyopathy patients with positive <sup>99 m<\/sup>Tc-labeled pyrophosphate scintigraphy findings. <i>Circ J<\/i> 2022; 86: 1113\u20131120, doi:10.1253\/circj.CJ-22-0118.","DOI":"10.1253\/circj.CJ-22-0118"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Sanchis K, Cariou E, Colombat M, Ribes D, Huart A, Cintas P, et al. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: Clinical and echocardiographic features, impact on mortality. <i>Amyloid<\/i> 2019; 26: 128\u2013138, doi:10.1080\/13506129.2019.1620724.","DOI":"10.1080\/13506129.2019.1620724"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: Challenges in risk stratification and treatment. <i>Can J Cardiol<\/i> 2020; 36: 416\u2013423, doi:10.1016\/j.cjca.2019.11.039.","DOI":"10.1016\/j.cjca.2019.11.039"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: Predictors, prevalence, and efficacy of rhythm control strategies. <i>JACC Clin Electrophysiol<\/i> 2020; 6: 1118\u20131127, doi:10.1016\/j.jacep.2020.04.019.","DOI":"10.1016\/j.jacep.2020.04.019"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Khanna S, Lo P, Cho K, Subbiah R. Ventricular arrhythmias in cardiac amyloidosis: A review of current literature. <i>Clin Med Insights Cardiol<\/i> 2020; 14: 1179546820963055, doi:10.1177\/1179546820963055.","DOI":"10.1177\/1179546820963055"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Cappelli F, Vignini E, Martone R, Perlini S, Mussinelli R, Sabena A, et al. Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis. <i>Circ Heart Fail<\/i> 2020; 13: e006619, doi:10.1161\/CIRCHEARTFAILURE.119.006619.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006619"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Zampieri M, Allinovi M, Olivotto I, Antonioli E, Gabriele M, Argiro A, et al. Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: A clash of cardio-toxicities? <i>Br J Haematol<\/i> 2021; 193: e27\u2013e31, doi:10.1111\/bjh.17399.","DOI":"10.1111\/bjh.17399"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Ochi Y, Kubo T, Baba Y, Sugiura K, Miyagawa K, Noguchi T, et al. Early experience of tafamidis treatment in Japanese patients with wild-type transthyretin cardiac amyloidosis from the Kochi amyloidosis cohort. <i>Circ J<\/i> 2022; 86: 1121\u20131128, doi:10.1253\/circj.CJ-21-0965.","DOI":"10.1253\/circj.CJ-21-0965"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Ichikawa Y, Oota E, Odajima S, Kintsu M, Todo S, Takeuchi K, et al. Impact of tafamidis on echocardiographic cardiac function of patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2023; 87: 508\u2013516, doi:10.1253\/circj.CJ-22-0683.","DOI":"10.1253\/circj.CJ-22-0683"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Benson MD, Breall J, Cummings OW, Liepnieks JJ. Biochemical characterisation of amyloid by endomyocardial biopsy. <i>Amyloid<\/i> 2009; 16: 9\u201314, doi:10.1080\/13506120802676914.","DOI":"10.1080\/13506120802676914"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Falk RH. Diagnosis and management of the cardiac amyloidoses. <i>Circulation<\/i> 2005; 112: 2047\u20132060, doi:10.1161\/CIRCULATIONAHA.104.489187.","DOI":"10.1161\/CIRCULATIONAHA.104.489187"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Kyle RA, Spittell PC, Gertz MA, Li CY, Edwards WD, Olson LJ, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. <i>Am J Med<\/i> 1996; 101: 395\u2013400, doi:10.1016\/S0002-9343(96)00229-X.","DOI":"10.1016\/S0002-9343(96)00229-X"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Inoue H, Fujiki A, Origasa H, Ogawa S, Okumura K, Kubota I, et al. Prevalence of atrial fibrillation in the general population of Japan: An analysis based on periodic health examination. <i>Int J Cardiol<\/i> 2009; 137: 102\u2013107, doi:10.1016\/j.ijcard.2008.06.029.","DOI":"10.1016\/j.ijcard.2008.06.029"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Matsumi H, Nakamura K, Eguchi E, Miyoshi T, Nakagawa K, Nishii N, et al. Low consultation rate of general population with atrial fibrillation. <i>Int Heart J<\/i> 2019; 60: 1303\u20131307, doi:10.1536\/ihj.19-062.","DOI":"10.1536\/ihj.19-062"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, et al. Atrial fibrillation in amyloidotic cardiomyopathy: Prevalence, incidence, risk factors and prognostic role. <i>Amyloid<\/i> 2015; 22: 147\u2013155, doi:10.3109\/13506129.2015.1028616.","DOI":"10.3109\/13506129.2015.1028616"},{"key":"29","doi-asserted-by":"publisher","unstructured":"29. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. <i>Arch Intern Med<\/i> 2006; 166: 1805\u20131813, doi:10.1001\/archinte.166.17.1805.","DOI":"10.1001\/archinte.166.17.1805"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Tan NY, Mohsin Y, Hodge DO, Lacy MQ, Packer DL, Dispenzieri A, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. <i>J Cardiovasc Electrophysiol<\/i> 2016; 27: 1167\u20131173, doi:10.1111\/jce.13046.","DOI":"10.1111\/jce.13046"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Barbhaiya CR, Kumar S, Baldinger SH, Michaud GF, Stevenson WG, Falk R, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. <i>Heart Rhythm<\/i> 2016; 13: 383\u2013390, doi:10.1016\/j.hrthm.2015.09.016.","DOI":"10.1016\/j.hrthm.2015.09.016"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Donnellan E, Wazni O, Kanj M, Elshazly MB, Hussein A, Baranowski B, et al. Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis. <i>Europace<\/i> 2020; 22: 259\u2013264, doi:10.1093\/europace\/euz314.","DOI":"10.1093\/europace\/euz314"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. <i>Heart Rhythm<\/i> 2008; 5: 235\u2013240, doi:10.1016\/j.hrthm.2007.10.016.","DOI":"10.1016\/j.hrthm.2007.10.016"},{"key":"34","doi-asserted-by":"publisher","unstructured":"34. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, et al. JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias. <i>Circ J<\/i> 2021; 85: 1104\u20131244, doi:10.1253\/circj.CJ-20-0637.","DOI":"10.1253\/circj.CJ-20-0637"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/5\/7\/5_CR-23-0022\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:26:58Z","timestamp":1715315218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/5\/7\/5_CR-23-0022\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-23-0022","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]},"article-number":"CR-23-0022"}}